Where does Proclara Biosciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Proclara Biosciences, Inc. ranks #32,942 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Proclara Biosciences, Inc. hold?

Proclara Biosciences, Inc. holds 8 US utility patents granted between 2016 and 2020, spanning 7 technology areas.

What is Proclara Biosciences, Inc.'s Innovation Score?

Proclara Biosciences, Inc. has an Innovation Score of 26.5 out of 100 (21st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Proclara Biosciences, Inc. focus on?

Proclara Biosciences, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 8 patents, ranking #2,286 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Proclara Biosciences, Inc.'s patent grant rate increasing or decreasing?

Proclara Biosciences, Inc.'s recent grant velocity is -67% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Proclara Biosciences, Inc.'s patents?

Proclara Biosciences, Inc.'s patents average 16.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Proclara Biosciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Proclara Biosciences, Inc.

USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, recorded in grant years 2016–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Proclara ranks #32,942 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 7 technology areas.

#32,942
of 49,997 US assignees by volume: 21st percentile
by Innovation Score (26.5/100): 16.0
avg claims per patent: -67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32942 · US Corporation #32,942 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,942/49,997
PHOTO-FINISH Procella Therapeutic…
CPC-NARROW A61P · 7 areas
INNOV-THIN 26.5/100
CLAIMS-RICH 16.0 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Procella Therapeutics AB (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Proclara’s 26.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (29%) Velocity 0.0 pts (0%) Breadth 9.4 pts (35%) Claim depth 9.6 pts (36%)

Qualcomm Incorporated · highest

85
Proclara Biosciences · this assignee

27
3D Lighting… · lowest

7

What this shows Proclara's Innovation Score is 26.5/100 (21st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Proclara?

Each dot is one of Proclara’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Proclara’s own 16.0 claims/patent is at or below the 16.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Proclara vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Proclara's grants concentrate

Proclara Biosciences, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2017. By volume, Proclara sits between ProMIS Neurosciences, Inc. and Proportional Technologies, Inc..

Promis Neuroscien…

8
Proverum

8
Procella Therapeu…

8
Process Retail Gr…

8
Progressive Globa…

8
Progressive Home…

8
Projecta Engineer…

8
Proportional

8
Proclara Bioscien… ◀

8

What this shows Proclara holds 8 patents at rank #32,946, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Proclara

By rank, the assignees closest to #32,946 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Proclara's primary technology class.

Proclara's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 21st percentile higher than 21% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Proclara Biosciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	25.0%
2017	1	12.5%
2018	2	25.0%
2019	1	12.5%
2020	2	25.0%

Which technologies does Proclara Biosciences, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 8

C07K - Peptides 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 3

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Proclara Biosciences, Inc.'s patent record in context - here's where to go next.

Proclara Biosciences, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #32,942 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Proclara Biosciences, Inc. against ProMIS Neurosciences, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.